Reportedly, patients having a history of ACS (acute coronary syndrome) or CHD (coronary heart disease) benefit additionally from treatment with a statin and ezetimibe, compared to the treatment with a statin alone. Nevertheless, there is no clue that the combination therapy of a statin with ezetimibe is better than the combination of a statin with alirocumab (lipid-lowering drug). These results were obtained by the researchers of the IQWiG (Institute for Quality and Efficiency in Health Care) in an existing benefit evaluation commissioned by the G-BA (Federal Joint Committee) in November 2018.
Cardiovascular diseases develop from the vascular system and the heart. These comprise of CHD, ACS, hypertension, stroke, and heart attack. Reportedly, in 2016 the cardiovascular diseases were the major cause of death worldwide, summing up for 31% of all deaths. Of all the reasons for death, 85% resulted from a stroke and heart attack. One of the biggest modifiable hazard factors for cardiovascular diseases is a higher LDL (low-density lipoprotein) cholesterol level. The decrease in LDL cholesterol is thus a significant aim in the prevention of cardiovascular diseases. For the individuals having a history of ACS or CHD, the recommendation of cholesterol-lowering drugs is given. At present, statins are the most commonly recommended class of drugs.
On a similar note, recently, new research stated that weight training—also known as resistance training—can aid people having PAD (peripheral artery disease) in reducing painful symptoms such as muscle cramps during walking. The study was led by medical researchers from the UNSW (University of New South Wales) and was published in the British Journal of Sports Medicine. In people with PAD, An accumulation of plaque in the arteries—caused by nicotine, high cholesterol, and other cardiovascular disease hazard factors—causes narrowing of the arteries and eventually reduce oxygen and blood supply to the legs that develop a cramping pain while walking.